The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Pfizer has been working on a potential vaccine for C. diff, but its first attempt missed ... updated formulation through mid-stage clinical testing. In the phase 3 ECOSPOR trial, patients who ...

The global health organization says the lack of rapid diagnostic tests results in undertreatment and overtreatment of ...

An advantage of CRS3123 compared with other treatments is its narrow spectrum, which targets C. difficile bacteria and stops toxin production while minimally affecting other microbes in the gut.

The study, published Sept. 30 in Open Forum Infectious Diseases, analyzed 45,049 patient records from 779 hospitals of adults who received treatment for C. diff infections before and after 2021.

With no approved vaccines to date, C. diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

We read every piece of feedback, and take your input very seriously.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

We read every piece of feedback, and take your input very seriously.